Welcome to All Things Biosimilar Podcast
Join Andrew Bourgoin, founder of Bourgoin Insights Group, as he introduces the All Things Biosimilar Podcast, an insightful series dedicated to the US biosimilars market. With over 15 years of industry experience, Andrew discusses the podcast's goal to deliver comprehensive analysis, timely market insights, and monitoring services. Learn about the 351K report and how it benefits both seasoned professionals and newcomers. Stay tuned for monthly episodes featuring key topics, special guests, and much more. Subscribe now to stay informed about the evolving biosimilars landscape.
00:00 Introduction to All Things Biosimilar Podcast
01:01 About Bourgoin Insights Group
01:38 The 351 K Report
01:57 Positive Feedback and New Ideas
02:41 Launching the Podcast
03:08 Future Plans and Engagement
04:14 Stay Connected
Connect with us!
Website:
www.Bourgoininsightsgroup.com
LinkedIn:
https://www.linkedin.com/company/bourgoin-insights-group
Music:
Bang Boom - Captain Joz
Production:
Maine Frame
Disclaimer:
Bourgoin Insights Group, LLC publishes market intelligence reports on various Biosimilars, Biologics, and the U.S. Biosimilar industry. All reports, both published publicly and those provided pursuant to part of a subscription to All Things Biosimilar are subject to the following disclaimer. A subscription to All Things Biosimilar automatically indicates acceptance of the disclaimer.
We, at Bourgoin Insights Group, LLC, gather information from various sources such paid databases, published reports, FDA databases, annual reports, surveys and media releases. This public information is collated in good faith in preparation of analysis and used on an as is and as available basis by us.
Episode Transcript
Have you ever wished that there was a podcast
series that offered insights,analysis, and information that
focused solely on the USbiosimilars market?
Me too.
Well, guess what?
Today's our lucky day.
(00:52):
Welcome to the All ThingsBiosimilar podcast.
I'm your host, Andrew Pergo, andif we haven't met, very nice to
meet you.
Earlier this year, I startedBurgo Insights Group and also
launched all things biosimilar.
This is an information platformthat focuses solely on the US
(01:13):
biosimilars market.
We aim to provide timelyanalysis, insights, and market
monitoring services to ourclients, all of which is
underpinned by a uniqueexperience.
My own.
Which includes over 15 years ofprofessional experience focused
solely on the US biosimilarsmarket.
(01:38):
At the beginning of the year, welaunched our.3 51 K report.
This is a weekly publicationthat comes out to individuals
that subscribe to our basic orpremium service and offers
information on what's happenedin the US biosimilars market
that week.
Along with my perspectives
Since launching the service, we've gotten some
(02:00):
really positive feedback.
We're hearing that we're savingteams a lot of time, that the
additional perspectives providedare extremely helpful.
And beyond that, it doesn'tmatter if it's somebody who's
worked in biosimilars for 10years or if maybe they're just
onboarding for the first time.
There's something in everysingle edition that gives them a
(02:22):
key takeaway.
They're learning.
Right, because this market isconstantly evolving and we're
all asked to learn something newall the time.
Another piece of feedback thatwe received was that there's a
lot of content in some of theissues, and it's not always easy
to get through it in a singlereading.
So been asked if potentially Icould consider doing an audio
(02:46):
version or a podcast to helpgive some optionality.
As to how to ingest all of theintelligence in the 3 51 K
report.
So getting that feedback, buyingsome lights, learning some video
editing software.
Here we are.
(03:06):
All things biosimilar podcast.
Now, what can we expect fromthis moving forward?
Well, great question.
Our goal is to start by doingprobably an episode once a
month.
We'll sift through all of thekey topics and information and
try to select three that we cantalk about in a way that
(03:28):
hopefully adds additional valueto those 3 51 K reports that
you're already getting.
In time we'll be able toincrease the cadence and also
probably add some interviews,some guests, some additional
information that you know you'vecome to learn to expect from all
things biosimilar.
(03:48):
Now, what will help us isfeedback from you all.
If there are topics that you'reinterested in, guess you want to
hear from, even things that youdon't care to hear about
anymore, let us know.
So with that, we'll see you nextepisode, which we plan to
release next week on a veryspecial 10th anniversary of the
(04:09):
launch of Zarzio and the openingof the US market.
To stay tuned and connected, youcan subscribe to this YouTube
channel.
You can follow us on LinkedIn atBergo Insights Group, or you can
head to bergo insightsgroup.com.
To learn more.
We hope you have a wonderfulrest of your week and we look
(04:31):
forward to what's next.
Popular Podcasts
Las Culturistas with Matt Rogers and Bowen Yang
Ding dong! Join your culture consultants, Matt Rogers and Bowen Yang, on an unforgettable journey into the beating heart of CULTURE. Alongside sizzling special guests, they GET INTO the hottest pop-culture moments of the day and the formative cultural experiences that turned them into Culturistas. Produced by the Big Money Players Network and iHeartRadio.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.